DDrare
Disease
Drug
Target Gene/Pathway
問合せ先
EN
Histamine ( DrugBank:
Histamine
)
1 disease
告示番号
疾患名
(ページ内リンク)
臨床試験数
13
多発性硬化症/視神経脊髄炎
3
13. 多発性硬化症/視神経脊髄炎
臨床試験数
:
3,342
/
薬物数
:
2,355
- (
DrugBank
:
406
) /
標的遺伝子数
:
269
-
標的パスウェイ数
:
241
10
50
100
ALL
diseases per page:
Showing 1 to 3 of 3 diseases
Filter by
Reset
No.
TrialID
Date_
enrollment
Date_
registration
Public_title
Scientific_title
Condition
Intervention
Primary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
Phase
Countries
1
NCT04764383
(
ClinicalTrials.gov
)
January 1, 2022
18/2/2021
Histamine
rgic Basis of Fatigue in Multiple Sclerosis
Histamine
rgic Basis of Fatigue in Multiple Sclerosis
Multiple Sclerosis
Drug: L-Histidine;Drug: Placebo;Drug: Lodosyn
University of Miami
NULL
Withdrawn
18 Years
60 Years
All
0
Phase 2
United States
2
NCT03266965
(
ClinicalTrials.gov
)
March 23, 2018
4/7/2017
Histamine
rgic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach
Histamine
rgic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach
Multiple Sclerosis
Drug: Carbidopa;Dietary Supplement: L-Histidine
University of Miami
United States Department of Defense
Completed
18 Years
60 Years
All
18
Phase 1
United States
3
NCT00630383
(
ClinicalTrials.gov
)
February 2008
27/2/2008
Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.
Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.
Multiple Sclerosis
Biological: Live Hookworm Larvae;Other:
Histamine
University of Nottingham
NULL
Withdrawn
18 Years
60 Years
Both
0
Phase 2
United Kingdom